Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted) (2019 - 2026)
Whitehawk Therapeutics (WHWK) reported EPS (Weighted Average and Diluted) of -$0.32 for Q1 2026, down 117.49% year-over-year from $1.83 in Q1 2025, and up 13.51% on a QoQ basis from -$0.37 in Q4 2025.
Whitehawk Therapeutics (WHWK) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.32 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 117.49% year-over-year to -$0.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.71 (down 1240.0% YoY) and the FY2025 annual result came in at -$0.33, up 86.02% from the prior year.
- EPS (Weighted Average and Diluted) advanced to -$0.32 in Q1 2026 per WHWK's latest filing, from -$0.37 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.83 in Q1 2025 and bottomed at -$0.87 in Q2 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.6 (2023), against an average of -$0.43.
- The widest annual swing landed in 2025, when EPS (Weighted Average and Diluted) surged 369.12%; it then slumped 117.49% in 2026.
- Tracing WHWK's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.48 in 2022, then retreated by 25.0% to -$0.6 in 2023, then decreased by 13.33% to -$0.68 in 2024, then jumped by 45.59% to -$0.37 in 2025, then grew by 13.51% to -$0.32 in 2026.
- Per Business Quant, the three latest WHWK EPS (Weighted Average and Diluted) figures stand at -$0.32 (Q1 2026), -$0.37 (Q4 2025), and -$0.26 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | -0.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.32 |
| Dec 31, 2025 | -0.37 |
| Sep 30, 2025 | -0.26 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | 1.83 |
| Dec 31, 2024 | -0.68 |
| Sep 30, 2024 | -0.46 |
| Jun 30, 2024 | -0.54 |
| Mar 31, 2024 | -0.68 |
| Dec 31, 2023 | -0.60 |
| Sep 30, 2023 | -0.60 |
| Jun 30, 2023 | -0.67 |
| Mar 31, 2023 | -0.57 |
| Dec 31, 2022 | -0.48 |
| Sep 30, 2022 | -0.68 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -0.66 |
| Dec 31, 2021 | 6.96 |
| Sep 30, 2021 | -9.17 |
| Jun 30, 2021 | -0.60 |
| Sep 30, 2020 | -0.07 |
| Jun 30, 2020 | 0.23 |
| Mar 31, 2020 | -0.10 |
| Sep 30, 2019 | -0.11 |
| Jun 30, 2019 | -0.14 |
| Mar 31, 2019 | -0.21 |